Literature DB >> 21833958

Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction.

Abha Maheshwari1, Ahmed Gibreel, Charalambos S Siristatidis, Siladitya Bhattacharya.   

Abstract

BACKGROUND: Gonadotrophin-releasing hormone agonists (GnRHa) are used in assisted reproduction technology (ART) cycles to prevent a luteinizing hormone surge. Various protocols have been described in the literature, such as long protocols (continuous and stop or reduce dose, long luteal, or long follicular protocol); short protocols and ultrashort protocols.
OBJECTIVES: To determine the most effective GnRHa protocol as an adjuvant to gonadotrophins in ART cycles. SEARCH STRATEGY: We searched the Cochrane Menstrual Disorders and Subfertility Group Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE, EMBASE, CINHAHL and PsycINFO. Reference lists of relevant articles were also searched. All the searches were updated to August 2010. SELECTION CRITERIA: Only randomised controlled trials comparing any two protocols of GnRHa in in vitro fertilization (IVF) or intra-cytoplasmic sperm injection (ICSI) cycles were included. DATA COLLECTION AND ANALYSIS: The primary outcome measure was live births per women. Secondary outcome measures were pregnancy rate, ongoing pregnancy rate, number of oocytes retrieved and amount of gonadotrophins used. Data were independently extracted in 2 x 2 tables by two authors. Odds ratios (OR) with 95% confidence intervals (CI) were calculated after verifying the presence of homogeneity of treatment effect across all trials. For continuous variables mean differences (MD) were calculated. MAIN
RESULTS: Of 29 included studies, 17 compared long with short protocols; two compared long with ultrashort protocols; four compared a follicular versus luteal start of GnRHa; three compared continuation versus stopping the GnRHa at the start of stimulation; three compared continuation of the same dose versus reduced dose of GnRHa and one compared a short versus short stop protocol.There was no evidence of a difference in the live birth rate but this outcome was only reported by three studies.There was evidence of a significant increase in clinical pregnancy rate (OR 1.50, 95% CI 1.16 to 1.93) in a long protocol when compared to a short protocol. That is there is a 50% increase in chance of achieving pregnancy if a long protocol is used as compared to a short protocol, although this difference could range from 16% to 93% increased chance of pregnancy. This difference did not persist when the meta-analysis was done only on the studies with adequate randomisation (OR 1.38, 95% CI 0.93 to 2.05).There was evidence of an increased number of oocytes (MD 1.61, 95% CI 0.18 to 3.04) obtained when a long protocol was used as compared to a short protocol. That is there is a 60% increase in the number of oocytes retrieved when a long protocol is used as compared to a short protocol, although this difference could range from 18% to 304% more oocytes.There was evidence of an increase (MD 12.90, 95% CI 3.29 to 22.51) in the requirement for gonadotrophins in long as compared to short protocols. That is approximately 12.9 more ampoules of gonadotrophins were consumed when a long protocol was used as compared to a short protocol. This difference could range from 3.29 to 22.51 more gonadotrophin ampoules.There was no evidence of a difference in any of the outcome measures for luteal versus follicular start of GnRHa and stopping versus continuation of GnRHa at the start of stimulation. AUTHORS'
CONCLUSIONS: The pregnancy rate was found to be higher when GnRHa was used in a long protocol as compared to a short or ultrashort protocol. There was no evidence of a difference in live birth rate, but this outcome was only reported by three studies. There was no evidence of a difference in the outcomes amongst various long protocols; nor that stopping or reducing GnRHa at the start of stimulation was associated with a reduced pregnancy rate. For all comparison, except a long versus short protocol, there was a lack of power.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21833958     DOI: 10.1002/14651858.CD006919.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  11 in total

Review 1.  Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews.

Authors:  Selma Mourad; Julie Brown; Cindy Farquhar
Journal:  Cochrane Database Syst Rev       Date:  2017-01-23

2.  Comparison of follicular fluid amphiregulin and EGF concentrations in patients undergoing IVF with different stimulation protocols.

Authors:  Nana Liu; Yanmin Ma; Rong Li; Hongyan Jin; Min Li; Xiang Huang; Huai L Feng; Jie Qiao
Journal:  Endocrine       Date:  2012-06-08       Impact factor: 3.633

Review 3.  Review of human genetic and clinical studies directly relevant to GnRH signalling.

Authors:  Stephanie B Seminara; A Kemal Topaloglu
Journal:  J Neuroendocrinol       Date:  2021-12-31       Impact factor: 3.870

Review 4.  Progress in understanding human ovarian folliculogenesis and its implications in assisted reproduction.

Authors:  Dong Zi Yang; Wan Yang; Yu Li; Zuanyu He
Journal:  J Assist Reprod Genet       Date:  2013-02       Impact factor: 3.412

Review 5.  Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles.

Authors:  Luiz Eduardo T Albuquerque; Leopoldo O Tso; Humberto Saconato; Maria Cecília R M Albuquerque; Cristiane R Macedo
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

6.  GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology.

Authors:  Ana Marcia M Cota; Joao Batista A Oliveira; Claudia G Petersen; Ana L Mauri; Fabiana C Massaro; Liliane F I Silva; Andreia Nicoletti; Mario Cavagna; Ricardo L R Baruffi; José G Franco
Journal:  Reprod Biol Endocrinol       Date:  2012-04-27       Impact factor: 5.211

7.  Vasodilators for women undergoing fertility treatment.

Authors:  Rosa B Gutarra-Vilchez; Xavier Bonfill Cosp; Demián Glujovsky; Andres Viteri-García; Fernando M Runzer-Colmenares; Maria José Martinez-Zapata
Journal:  Cochrane Database Syst Rev       Date:  2018-10-12

8.  Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report.

Authors:  John I-Chiang Chang; Joseph Bucci
Journal:  J Med Case Rep       Date:  2016-11-11

9.  An extremely patient-friendly and efficient stimulation protocol for assisted reproductive technology in normal and high responders.

Authors:  Chen-Yu Huang; Guan-Yeu Chen; Miawh-Lirng Shieh; Hsin-Yang Li
Journal:  Reprod Biol Endocrinol       Date:  2018-03-05       Impact factor: 5.211

10.  Testicular sperm is superior to ejaculated sperm for ICSI in cryptozoospermia: An update systematic review and meta-analysis.

Authors:  Yi-No Kang; Ya-Wen Hsiao; Chien-Yu Chen; Chien-Chih Wu
Journal:  Sci Rep       Date:  2018-05-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.